PEPTIDE

Teduglutide

GLP-2 analog resistant to DPP-4; FDA-approved (Gattex) to promote intestinal mucosal growth and reduce parenteral nutrition need in SBS.

BIOGATE · GREEN | POSTERIOR 12.3% | MW 3752.1 | 33AA

SEQUENCE

HGDGSFSDEMNTILDNLAARDFINWLIQTKITD

Modifications: Gly² substitution from native GLP-2

PDA-V1 chain of custody

Outer hash

e700e6dee800e871e500e3b8e600e54beb00ed2aec00eebde900ea0

Merkle root

7-b4c38997a4c3706794c3573784c33e07f4c3ee57e4c3d527d4c3bbf7c4c3a2c

Inputs

69-ae245e6aae25f167ae213868ae22cb6dae2aaa6eae2c3d6bae27846

TEE attestation

48-f0b16b47f0afd84af0b49149f0b2fe4cf0b7b74bf0b6244ef0badd4df0b94a

Living Outcome Oracle

± =11.1 ² =79.5 **P(success) = 12.3%**

95% CI [0.3%, 24.3%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A 2011 · Gut

Teduglutide reduces need for parenteral support in short-bowel syndrome

Jeppesen PB et al.

PMID 21873748